132 related articles for article (PubMed ID: 21060171)
1. Comparison of demographic data and immunosupression protocol in patients with and without malignancy after kidney transplantation.
Akbarzadehpasha A; Oliaei F; Asrari MR; Alizadeh-Navaei R
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1044-7. PubMed ID: 21060171
[TBL] [Abstract][Full Text] [Related]
2. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma.
Ingvar A; Smedby KE; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
Nephrol Dial Transplant; 2010 Aug; 25(8):2764-71. PubMed ID: 19729465
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of human herpes virus-8 in renal transplant recipients: a single center study from Iran.
Ahmadpoor P; Ilkhanizadeh B; Sharifzadeh P; Makhdoomi K; Ghafari A; Nahali A; Yekta Z; Noroozinia F
Transplant Proc; 2007 May; 39(4):1000-2. PubMed ID: 17524874
[TBL] [Abstract][Full Text] [Related]
5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
Azarpira N; Aghdaie MH; Malekpour Z
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
[TBL] [Abstract][Full Text] [Related]
7. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.
Wieneke H; Otte B; Lang D; Heidenreich S
Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953
[TBL] [Abstract][Full Text] [Related]
9. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
10. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
11. Non-lymphoid cancer after liver transplantation.
Frezza EE; Fung JJ; van Thiel DH
Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
13. A long-term study on hyperlipidemia in stable renal transplant recipients.
Tse KC; Lam MF; Yip PS; Li FK; Lai KN; Chan TM
Clin Transplant; 2004 Jun; 18(3):274-80. PubMed ID: 15142048
[TBL] [Abstract][Full Text] [Related]
14. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
[TBL] [Abstract][Full Text] [Related]
16. [Cancer after kidney transplantation and immunosuppression].
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Antova Z; Spasovski G; Vlckova-Laskovska M; Zografski G
Ann Urol (Paris); 2000 Oct; 34(5):336-9. PubMed ID: 11144722
[TBL] [Abstract][Full Text] [Related]
17. Neoplastic skin lesions in Iranian renal transplant recipients: the role of immunosuppressive therapy.
Zamanian A; Farshchian M
J Drugs Dermatol; 2007 Jul; 6(7):703-6. PubMed ID: 17763593
[TBL] [Abstract][Full Text] [Related]
18. Impact of cardiovascular risk factors on the outcome of renal transplantation.
Moghimi M; Falaknazi K; Bagheri N
Saudi J Kidney Dis Transpl; 2010 May; 21(3):438-42. PubMed ID: 20427865
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
20. Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies.
Glowacki F; Al Morabiti M; Lionet A; Labalette M; Provot F; Noel C; Hazzan M
Transplant Proc; 2009 Oct; 41(8):3323-5. PubMed ID: 19857742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
